Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

Combined Blockage of E-Selectin and CXCR4 (GMI-1359) Enhances Anti-Leukemia Effect of FLT3 Inhibition (Sorafenib) and Protects Hematopoiesis in Pre-Clinical AML Models

Weiguo Zhang, MD PhD, Kyung Hee Chang, PhD, Mahesh Basyal, BS, Yannan Jia, Lauren B Ostermann, BS, William E. Fogler, PhD, John L. Magnani, PhD, M Anna Zal, BS., MS, Tomasz Zal, PhDMSc, Michael Andreeff, MD PhD

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-140984

Published: 2020

Journal Articles

Dual CXCR4 and E-Selectin Inhibition (GMI-1359) Rapidly Increases AML Cellular Motility Prior to Intravasation and Vascular Niche Depletion Observed By Intravital Bone Marrow Two-Photon Microscopy

Tomasz Zal, PhDMSc, Malgorzata Anna Zal, MSc, Mateusz Rytelewski, PhD, Kyung Hee Chang, PhD, Rodrigo Jacamo, PhD, William E. Fogler, PhD, John L. Magnani, PhD, Michael Andreeff, MD PhD

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-143420

Published: 2020

Journal Articles

Targeting E-Selectin with GMI-1271 Overcomes Microenvironment-Mediated Resistance to Venetoclax/HMA Therapy

Kyung Hee Chang, PhD, Muharrem Muftuoglu, Weiguo Zhang, MD PhD, Mahesh Basyal, BSc, Lauren B Ostermann, BS, William E. Fogler, PhD, John L. Magnani, PhD, Michael Andreeff, MD PhD

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-141957

Published: 2020

Journal Articles

Restoration of Normal Blood Flow in Mouse Models of Sickle Cell Vaso-Occlusion Following Intravenous or Subcutaneous Administration of a Highly Potent E-Selectin Specific Inhibitor

Madhan Thamilarasan, PhD, William E. Fogler, PhD, John L. Magnani, PhD, Rahima Zennadi, PhD

Blood (2020) 136 (Supplement 1): 17.

https://doi.org/10.1182/blood-2020-140276

Published: 2020

Journal Articles

Early Initiation of Treatment with Rivipansel for Acute Vaso-Occlusive Crisis in Sickle Cell Disease (SCD) Achieves Earlier Discontinuation of IV Opioids and Shorter Hospital Stay: Reset Clinical Trial Analysis

Carlton D. Dampier, MD, Marilyn J. Telen, MD, Ted Wun, MD, Wally R Smith, MD, R. Clark Brown, MD PhD, Payal Desai, MD, Fuad A El Rassi, MD, Julie Kanter, MD, Beng R. Fuh, MD, Yves D. Pastore, MD, Jennifer A. Rothman, MD, James G. Taylor, MD, David Readett, BM, BS, MRCP, Jay N Lozier, MDPhD, John L. Magnani, PhD, Helen M Thackray, MD, Kathryn L. Hassell, MD

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-134803

Published: 2020

Journal Articles

CD162 Is a Key E-Selectin Receptor Promoting Acute Myeloid Leukemia Chemo-Resistance in the Bone Marrow Niche

Johanna D Erbani, Joshua Tay, PhD, Valerie Barbier, Masters, Jean-Pierre Levesque, PhD, John L. Magnani, PhD, Ingrid G Winkler, PhD

Blood (2019) 134 (Supplement_1): 907.

https://doi.org/10.1182/blood-2019-132233

Published: 2019

Journal Articles

High E-Selectin Ligand Expression Contributes to Chemotherapy-Resistance in Poor Risk Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML) Patients and Can be Overcome with the Addition of Uproleselan

Daniel J. DeAngelo, MD PhD, Brian A Jonas, MD PhD, Jane L. Liesveld, MD, Dale L. Bixby, MD, Anjali S. Advani, MD, Paula Marlton, MBBS (Hons), FRACP, FRCPA, Michael E O'Dwyer, MD, William E. Fogler, PhD, John L. Magnani, PhD, Mary M Chen, MD PhD, Eric J. Feldman, MD, Helen M Thackray, MD, Pamela S. Becker, MD PhD

Blood (2019) 134 (Supplement_1): 2690.

https://doi.org/10.1182/blood-2019-123744

Published: 2019

Journal Articles

Synergistic Targeting of BTK and E-Selectin/CXCR4 in the Microenvironment of Mantle Cell Lymphomas

Mahesh Basyal, Weiguo Zhang, MD PhD, Nalini B Patel, Sujan Piya, PhD, Hongying Zhang, MD PhD, William E. Fogler, PhD, William G Rice, PhD, John L. Magnani, PhD, Gautam M. Borthakur, MD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 3802.

https://doi.org/10.1182/blood-2019-126030

Published: 2019

Journal Articles

Transcriptome Profiling of Glycosylation Genes Defines Correlation with E-Selectin Ligand Expression and Clinical Outcome in AML

Amanda R. Leonti, MS, Laura Pardo, Todd A. Alonzo, PhD, Robert B. Gerbing, Lisa Eidenschink Brodersen, PhD, Rhonda E. Ries, MA, Jenny L. Smith, MSc, MD, Quy Le, PhD, Richard Aplenc, MD PhD, E. Anders Kolb, MD, John L. Magnani, PhD, William E. Fogler, PhD, Michael R. Loken, PhD, Soheil Meshinchi, MD PhD

Blood (2019) 134 (Supplement_1): 3772.

https://doi.org/10.1182/blood-2019-124525

Published: 2019

Journal Articles

A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia

Daniel J. DeAngelo, MD PhD, Harry P. Erba, MD PhD, Brian A Jonas, MD PhD, Michael E O'Dwyer, MD, Paula Marlton, MBBS (Hons), FRACP, FRCPA, Gerwin Huls, MD PhD, Jane L. Liesveld, MD, Brenda Cooper, MD, Bhavana Bhatnagar, DO, Geoffrey L. Uy, MD, Gavin Cull, MB, BS, FRACP, FRCPA, Michael B. Armstrong, MD PhD, William E. Fogler, PhD, Mary M Chen, MD PhD, John L. Magnani, PhD, Helen M Thackray, MD, Eric J. Feldman, MD, Anjali S. Advani, MD, Pamela S. Becker, MD PhD

Blood (2019) 134 (Supplement_1): 2650.

https://doi.org/10.1182/blood-2019-123816

Published: 2019

Journal Articles

Blocking Vascular Niche E-Selectin Dampens AML Stem Cell Regeneration/Survival Potential In Vivo By Inhibiting MAPK/ERK and PI3K/AKT Signalling Pathways

Ingrid G Winkler, PhD, Valerie Barbier, Masters, Joshua Tay, PhD, Jean-Pierre Levesque, PhD, John L. Magnani, PhD, Corrine E Fiveash, BSc(Hons), Johanna D Erbani

Blood (2019) 134 (Supplement_1): 2657.

https://doi.org/10.1182/blood-2019-132212

Published: 2019

Journal Articles

Uproleselan (GMI-1271), an E-Selectin Antagonist, Improves the Efficacy and Safety of Chemotherapy in Relapsed/Refractory (R/R) and Newly Diagnosed Older Patients with Acute Myeloid Leukemia: Final, Correlative, and Subgroup Analyses

Daniel J. DeAngelo, MD, Brian A. Jonas, MD PhD, Jane L. Liesveld, MD, Dale L. Bixby, MD PhD, Anjali S. Advani, MD, Paula Marlton, Michael E O'Dwyer, MD, William E Fogler, PhD, Curt D Wolfgang, PhD, John L Magnani, PhD, Helen M Thackray, MD, Pamela S. Becker, MD

Blood (2018) 132 (Supplement 1): 331.

https://doi.org/10.1182/blood-2018-99-114286

Published: 2018

Journal Articles

Vascular E-Selectin Acts As a Gatekeeper Inducing Commitment and Loss of Self-Renewal in HSC Transmigrating through the Marrow Vasculature

Ingrid G Winkler, PhD, Valerie Barbier, Masters, Jessica Lowe, BSc(Hons), Joshua Tay, PhD, John L Magnani, PhD, Paula Marlton, Anthony K Mills, FRACP, FRCPA, MBBS, Andrew Perkins, MBBS, PhD FRCPA, FRACP, Corrine E Fiveash, BSc(Hons), Johanna M Erbani, PhDstudent, Jean-Pierre Levesque, PhD

Blood (2018) 132 (Supplement 1): 4552.

https://doi.org/10.1182/blood-2018-99-120376

Published: 2018

Journal Articles

A Novel and Potent Inhibitor of E-Selectin, GMI-1687, Attenuates Thrombus Formation and Augments Chemotherapeutic Intervention of AML in Preclinical Models Following Subcutaneous Administration

John Peterson, PhD, Myung-Gi Baek, PhD, Silvia Locatelli-Hoops, PhD, Ji-Won Lee, PhD, Lingquan Deng, PhD, David A Stewart, Theodore AG Smith, PhD, Daniel Durant Myers, DVM, MPH, William E Fogler, PhD, John L Magnani, PhD

Blood (2018) 132 (Supplement 1): 4678.

https://doi.org/10.1182/blood-2018-99-116779

Published: 2018

Journal Articles

A Novel Glycomimetic Compound (GMI-1757) with Dual Functional Antagonism to E-Selectin and Galectin-3 Demonstrates Inhibition of Thrombus Formation in an Inferior Vena Cava Model

John Peterson, PhD, Yusuf Vohra, PhD, Daniel Durant Myers, DVM, MPH, Silvia Locatelli-Hoops, PhD, Ji-Won Lee, PhD, Lingquan Deng, PhD, Theodore AG Smith, PhD, William E Fogler, PhD, John L Magnani, PhD

Blood (2018) 132 (Supplement 1): 2211.

https://doi.org/10.1182/blood-2018-99-118122

Published: 2018

Journal Articles

E-Selectin Ligand Expression By Leukemic Blasts Is Associated with Prognosis in Patients with AML

Sylvia S Chien, Jin Dai, PhD, John L Magnani, PhD, Taylor S Sekizaki, William E Fogler, PhD, Helen M Thackray, MD, Kelda Gardner, PA-C, Elihu H. Estey, MD, Pamela S Becker, MD PhD

Blood (2018) 132 (Supplement 1): 1513.

https://doi.org/10.1182/blood-2018-99-119449

Published: 2018

Journal Articles

GMI-1271 Improves Efficacy and Safety of Chemotherapy in R/R and Newly Diagnosed Older Patients with AML: Results of a Phase 1/2 Study

Daniel J. DeAngelo, MD, Brian A Jonas, MD PhD, Jane L. Liesveld, MD, Dale L. Bixby, Anjali S. Advani, MD, Paula Marlton, MBBS, Michael O'Dwyer, MD, John L Magnani, PhD, Helen M. Thackray, MD, Pamela S. Becker, MD PhD

Blood (2017) 130 (Supplement 1): 894.

https://doi.org/10.1182/blood.V130.Suppl_1.894.894

Published: 2017

Journal Articles

Vascular E-Selectin Mediates Chemo-Resistance in Acute Myeloid Leukemia Initiating Cells Via Canonical Receptors PSGL-1 (CD162) and Hcell (CD44) and AKT Signaling

Ingrid G Winkler, PhD, Johanna M Erbani, PhDstudent, Valerie Barbier, Masters, Julie M Davies, PhD, Joshua Tay, PhDstudent, Corrine E Fiveash, BSc(Hons), Jessica Lowe, BSc(Hons), Michael Tallack, MDPhD, John L Magnani, PhD, Jean-Pierre Levesque, PhD

Blood (2017) 130 (Supplement 1): 793.

https://doi.org/10.1182/blood.V130.Suppl_1.793.793

Published: 2017

Journal Articles

Glycomimetic Antagonist of E-Selectin, GMI-1271, Enhances Therapeutic Activity of the Hypomethylating Agent, 5-Azacitidine, in the KG1 Model of AML

William E Fogler, PhD, Theodore AG Smith, PhD, Ji-Won Lee, PhD, John L Magnani, PhD

Blood (2017) 130 (Supplement 1): 5065.

https://doi.org/10.1182/blood.V130.Suppl_1.5065.5065

Published: 2017

Journal Articles

Vascular E-Selectin Protects Leukemia Cells from Chemotherapy By Directly Activating Pro-Survival NF-Kb Signalling - Therapeutic Blockade of E-Selectin Dampens NF-Kb Activation

Ingrid G Winkler, PhD, Valerie Barbier, Micheal Ward, PhD, Michael Tallack, PhD MD, Jessica Lowe, Julie Davies, Johanna Erbani, John L Magnani, PhD, Jean-Pierre Levesque, PhD

Blood (2016) 128 (22): 2823.

https://doi.org/10.1182/blood.V128.22.2823.2823

Published: 2016

NARROW

Combined Blockage of E-Selectin and CXCR4 (GMI-1359) Enhances Anti-Leukemia Effect of FLT3 Inhibition (Sorafenib) and Protects Hematopoiesis in Pre-Clinical AML Models

Dual CXCR4 and E-Selectin Inhibition (GMI-1359) Rapidly Increases AML Cellular Motility Prior to Intravasation and Vascular Niche Depletion Observed By Intravital Bone Marrow Two-Photon Microscopy

Targeting E-Selectin with GMI-1271 Overcomes Microenvironment-Mediated Resistance to Venetoclax/HMA Therapy

Restoration of Normal Blood Flow in Mouse Models of Sickle Cell Vaso-Occlusion Following Intravenous or Subcutaneous Administration of a Highly Potent E-Selectin Specific Inhibitor

Early Initiation of Treatment with Rivipansel for Acute Vaso-Occlusive Crisis in Sickle Cell Disease (SCD) Achieves Earlier Discontinuation of IV Opioids and Shorter Hospital Stay: Reset Clinical Trial Analysis

CD162 Is a Key E-Selectin Receptor Promoting Acute Myeloid Leukemia Chemo-Resistance in the Bone Marrow Niche

High E-Selectin Ligand Expression Contributes to Chemotherapy-Resistance in Poor Risk Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML) Patients and Can be Overcome with the Addition of Uproleselan

Synergistic Targeting of BTK and E-Selectin/CXCR4 in the Microenvironment of Mantle Cell Lymphomas

Transcriptome Profiling of Glycosylation Genes Defines Correlation with E-Selectin Ligand Expression and Clinical Outcome in AML

A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia

Blocking Vascular Niche E-Selectin Dampens AML Stem Cell Regeneration/Survival Potential In Vivo By Inhibiting MAPK/ERK and PI3K/AKT Signalling Pathways

Uproleselan (GMI-1271), an E-Selectin Antagonist, Improves the Efficacy and Safety of Chemotherapy in Relapsed/Refractory (R/R) and Newly Diagnosed Older Patients with Acute Myeloid Leukemia: Final, Correlative, and Subgroup Analyses

Vascular E-Selectin Acts As a Gatekeeper Inducing Commitment and Loss of Self-Renewal in HSC Transmigrating through the Marrow Vasculature

A Novel and Potent Inhibitor of E-Selectin, GMI-1687, Attenuates Thrombus Formation and Augments Chemotherapeutic Intervention of AML in Preclinical Models Following Subcutaneous Administration

A Novel Glycomimetic Compound (GMI-1757) with Dual Functional Antagonism to E-Selectin and Galectin-3 Demonstrates Inhibition of Thrombus Formation in an Inferior Vena Cava Model

E-Selectin Ligand Expression By Leukemic Blasts Is Associated with Prognosis in Patients with AML

GMI-1271 Improves Efficacy and Safety of Chemotherapy in R/R and Newly Diagnosed Older Patients with AML: Results of a Phase 1/2 Study

Vascular E-Selectin Mediates Chemo-Resistance in Acute Myeloid Leukemia Initiating Cells Via Canonical Receptors PSGL-1 (CD162) and Hcell (CD44) and AKT Signaling

Glycomimetic Antagonist of E-Selectin, GMI-1271, Enhances Therapeutic Activity of the Hypomethylating Agent, 5-Azacitidine, in the KG1 Model of AML

Vascular E-Selectin Protects Leukemia Cells from Chemotherapy By Directly Activating Pro-Survival NF-Kb Signalling - Therapeutic Blockade of E-Selectin Dampens NF-Kb Activation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only